FCCC LOGO Faculty Publications
Weiner Louis M
Fully Human Therapeutic Monoclonal Antibodies
Journal of Immunotherapy. 2006 ;29(1) :1-9
PMID: AN 2005:1323571   
Back to previous list
Abstract
Monoclonal antibody (mAb) therapy has been facilitated by a no. of technol. advances over the past 30 years. Whereas hybridoma development of murine mAbs was requisite for the development of mAbs as drugs, the inherent immunogenicity of rodent sequences in humans has presented obstacles to the clin. application of mAbs. Sensitization to mAb therapeutics poses significant risk to the patient and may blunt the efficacy of these therapies. The advent of chimeric antibodies lessened but did not eliminate the rodent content of mAbs; thus, immunogenicity remained a concern. Further elimination of rodent sequences enabled the prodn. of humanized mAbs, followed by current technol. using phage display and, finally, transgenic mice technol., which allows for the generation of fully human therapeutic mAbs. The reduced immunogenicity of this new generation of mAbs is expected to enhance efficacy, safety, and ease of use. In addn. to providing replacements for existing mAb drugs, new technologies have greatly facilitated the optimization and modification of mAbs, opening numerous therapeutic avenues. [on SciFinder (R)]
Notes
15 Immunochemistry Department of Medical Oncology, .,Fox Chase Cancer Center,Philadelphia,PA,USA. Journal 1524-9557 written in English.